Pancreatic Cancer Clinical Trial
Official title:
Pancreaticoduodenectomy: Outcomes of a Complex Surgical Procedure From a Developing Country
ABSTRACT
BACKGROUND Pancreaticoduodenectomy (PD) plays an integral part in the management of
pancreatic, periampullary and duodenal cancers along with few other pathologies of this
region. Despite advances in surgery PD continues to have significant morbidity and noteworthy
mortality. The aim of this study is to provide an in-depth report on the patient
characteristics, indications and the outcomes of PD) in a tertiary cancer hospital in
Pakistan.
MATERIALS AND METHODS:
The study population included patients who underwent PD between January 1st 2014 and march
31st 2019, at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in
Pakistan. The Data was retrospectively analyzed from the Hospital Information System (HIS),
which is a prospectively maintained patient electronic database of SKMCH&RC. Patient
characteristics, procedural details and post-operative outcomes according to internationally
accepted definitions were reported.
KEYWORDS: Whipple's procedure, Pancreaticoduodenectomy, Pancreaticogastrostomy, lower middle
income, pancreatic fistula, periampullary cancer.
INTRODUCTION:
Pancreatic cancer is one of the most common cancer worldwide and ranks 7th as the leading
cause of death among all cancers.The estimated 5 year survival of pancreatic cancer is very
poor i.e. 5%. Apart from cancer there is a plethora of benign and pre-malignant pancreatic
lesions that can manifest symptoms in patients.
Surgery plays an integral part in the management of pancreatic lesions.
Pancreaticoduodenectomy (PD) is a considered to be one of the most complex and morbid
surgical procedures. The first case series published by Allan Whipple in 1935 reported the
procedure related mortality in excess of 25 percent. With the advancements in surgical
techniques, perioperative and critical care management, mortality rate has dropped down to
less than 5 percent in high volume centers. However, morbidity remains high with some studies
reporting up to 70 percent .
There have been some studies, with small cohort and limited follow up periods, reporting on
outcomes of PD in Pakistan .To our knowledge, no published study has focused on detailed
surgical outcomes and long term follow up. We do not know the long term outcomes after PD in
Pakistan and most information is based on a western literature which may not be applicable to
a Pakistani cohort of patients. SKMCH&RC being a dedicated cancer centre and tertiary care
hospital of the country receives a high number of referrals of patients requiring this
complex procedure in Pakistan.
Every patient that is referred to our hospital has a detailed history and examination in the
walk-in clinic. Every case undergoes a pancreatic protocol Computerised Tomograph scan(CT)
and where appropriate interventions like Endoscopic Retrograde Cholangiography (ERCP) with or
without stent placement, Endoscopic Ultra-sound or Percutaneous Trans-hepatic Cholangiogram
(PTC) are undertaken. Every case is discussed in our Multi-Disciplinary Team (MDT) meeting
comprising of trained hepatobiliary surgeons, gastroenterologists, diagnostic and
interventional radiologists, pathologists, medical and radiation oncologists. Patients with
border-line operable confirmed pancreatic cancers undergo neo-adjuvant treatment, whereas
resectable lesions undergo upfront PD.investigators work at a paperless hospital and all
patient data is put real time into a computerised Hospital Information System (HIS) by all
cadres including nurses, allied health professionals and doctors. The hospital has a unique
in-house developed computerised patient management system (HIS) that collects all patient
information in real time including patient demographics, investigations, Multi-Disciplinary
Team discussions, Nursing assessments, outpatient, operative notes and post- operative
outcomes. As the data is collected in real time and stored, it allows for accurate
retrospective review of the data.
The aim of this study is to provide a detailed analysis of the patient characteristics,
indications, post-operative and intermediate term outcomes for PD in a Pakistani cohort of
patients. This will provide a reference point for physicians when they counsel their patients
regarding PD outcomes in Pakistan and also help define areas of potential improvement in the
future.
METHODOLOGY:
Patients:
All patients undergoing PD from 1st January 2014 till 31st March 2019 at SKMCH&RC, Pakistan
were retrospectively evaluated from a prospectively maintained database using the HIS system.
The cohort of patients selected included malignant, pre-malignant and benign pathologies.
Exclusion criteria included patients that did not undergo PD after exploratory laparotomy due
to metastatic disease or with involvement of celiac, superior mesenteric or hepatic arteries.
The ethical approval was sought from Institutional Review Board (IRB) of SKMCH & RC vide
number EX-24-10-19-01.
Variables:
Variables recorded were age, gender, co-morbidities, American-Society of Anesthesiologists
score (ASA), pre-operative histopathology, clinical staging, surgical details, post-operative
complications, mortality (30 & 90 day), length of stay, and survival outcomes.
Pancreatic fistula was recorded as defined by ISGPF 2016 updated criteria.
Post-Pancreatectomy Hemorrhage (PPH) was recorded as defined by International Study Group on
Pancreatic Surgery (ISGPS) 2007 classification. Morbidity was recorded according to
Clavien-Dindo classification.
Statistical analyses:
Calculations were performed with Statistical Package for the Social Sciences (SPSS Ver20) for
Windows. Data was described using median with minimum and maximum value for skewly
distributed quantitative variables. For categorical variables, number of observations and
percentages were reported. For survival analyses Kaplan-Miere Curve was applied. The study is
in compliance with the SKMCH&RC guidelines on research involving human subjects.
ETHICAL APPROVAL:
Ethical approval was obtained from Institutional Review Board (IRB) of Shaukat Khanum
Memorial Cancer Hospital and Research Centre, prior to the commencement of study.
PATIENTS' CONSENT:
Informed consent was taken from every patient about data collection, analysis and research
publication.
DECLARATIONS OF INTEREST:
None
FUNDING:
The research did not receive any specific grant from funding agencies in the public,
commercial, or not-for-profit sectors.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|